{
    "brief_title": "A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer",
    "phase": "Phase 2",
    "drugs": "['Megestrol Acetate 160Mg Tablet', 'Anastrozole 1Mg Tablet', 'Letrozole 2.5Mg Tablet', 'Exemestane 25 MG', 'Tamoxifen 20Mg Tablet', 'Fulvestrant 50Mg Solution for Injection']",
    "drugs_list": [
        "Megestrol Acetate 160Mg Tablet",
        "Anastrozole 1Mg Tablet",
        "Letrozole 2.5Mg Tablet",
        "Exemestane 25 MG",
        "Tamoxifen 20Mg Tablet",
        "Fulvestrant 50Mg Solution for Injection"
    ],
    "diseases": "['Breast Neoplasm']",
    "diseases_list": [
        "Breast Neoplasm"
    ],
    "enrollment": "20.0",
    "inclusion_criteria": "inclusion criteria: \n\n Metastatic breast cancer with ER and/or PR positive (primary tumor) \n\n Metastatic site amenable to biopsy \n\n ",
    "exclusion_criteria": ": \n\n Platelet count below 100,000 / mm3 \n\n Renal or hepatic impairment \n\n Coagulation disorder",
    "brief_summary": "This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.",
    "NCT_ID": "NCT03024580"
}